Tekla Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Tekla Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-49,036	Closed	-$3.42M	–	214
2020 Q2	$3.42M	Hold	49,036	–	–	0.13%	128
2020 Q1	$2.23M	Sell	49,036 -16,615	-25%	-$942K	0.1%	129
2019 Q4	$4.27M	Sell	65,651 -4,969	-7%	-$332K	0.16%	119
2019 Q3	$4.38M	Hold	70,620	–	–	0.19%	89
2019 Q2	$5.03M	Buy	70,620 +22,698	+47%	+$1.67M	0.21%	90
2019 Q1	$3.76M	Buy	47,922 +5,523	+13%	+$418K	0.15%	109
2018 Q4	$3.59M	Buy	42,399 +28,068	+196%	+$2.99M	0.15%	101
2018 Q3	$2.45M	Buy	+14,331	New	+$2.16M	0.09%	136
2015 Q1	–	Sell	-110,928	Closed	-$3.68M	–	119
2014 Q4	$3.68M	Hold	110,928	–	–	0.17%	77
2014 Q3	$3.25M	Buy	+110,928	New	+$3.68M	0.15%	100

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Tekla Capital Management's LGND Position: Q3 2020 in Review

Tekla Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q3 2020, closing a stake of 49,036 shares — an estimated $3.42M sold.

Tekla Capital Management first reported a position in LGND in Q3 2014 and held it in 10 quarters. The position peaked at $5.03M in Q2 2019. 252 funds tracked by Wall St. Rank hold LGND as of Q3 2020.

Tekla Capital Management reported no remaining Ligand Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Tekla Capital Management sold 49,036 Ligand Pharmaceuticals shares in Q3 2020, an estimated $3.42M.
Tekla Capital Management first reported a position in Ligand Pharmaceuticals in Q3 2014 and held it in 10 quarters.
Tekla Capital Management's Ligand Pharmaceuticals position peaked at $5.03M in Q2 2019.
252 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2020.

Based on Tekla Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.